ombitasvir (Viekira Pak) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ombitasvir (ABT-267) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, has favorable pharmacokinetic characteristics and is active in the picomolar range against genotype 1 - 6. In 2015, it was approved by FDA for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1.   NCATS

Chemistry

  • SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)C=C5
  • InChIKey: PIDFDZJZLOTZTM-KHVQSSSXSA-N
  • Mol. Mass: 894.1091
  • ALogP: 7.69
  • ChEMBL Molecule:
    ombitasvir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( ritonavir (Norvir), ombitasvir (Viekira Pak), paritaprevir (viekira pak) )
|
( ritonavir (Norvir), ombitasvir (Viekira Pak), paritaprevir (viekira pak), dasabuvir (Exviera) - other names: dasabuvir, ombitasvir, paritaprevir, and ritonavir, viekira xr )

Alternative names

abt-267 | abt-333 | dimethyl ([(2s,5s)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2s)pyrrolidine-2,1-diyl[(2s)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate | ombitasvir | ombitasvir heminonahydrate | ombitasvir hydrate | ombitasvir / paritaprevir / ritonavir | ombitsavir

Organizations (30)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (3)


 

Hepatitis C

Hepatitis C, Chronic

Infections

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Fibrosis (Phase 3)

Genotype (Phase 3)

Healthy Volunteers (Phase 1)

Hepacivirus (Phase 4)

Hepatitis B (Phase 2/Phase 3)

Hepatitis C ()

Hepatitis C, Chronic ()

Hepatitis Viruses (Phase 4)

HIV (Phase 3)

HIV Infections (Phase 2)

Infections ()

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 4)

Liver Cirrhosis (Phase 3)

Pharmacology (Phase 1)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 69
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue